OcellO
OcellO was a Leiden-based biotech providing high content imaging and in vitro drug screening services to pharmaceutical and biotech companies. Founded in 2011, it was acquired by and fully integrated into Crown Bioscience's preclinical services portfolio.
- Company typePrivate
- Founded2011
- HeadquartersLeiden, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What OcellO does
OcellO was a Dutch biotechnology company founded in 2011 and headquartered in Leiden, Netherlands. The company specialized in high content imaging and in vitro drug screening services, operating a small team of 1-10 employees focused on cellular analysis for preclinical drug discovery applications. Its core technology stack included proprietary high content imaging platforms, cancer cell line panels, and patient-derived organoid models designed to provide more predictive in vitro drug screening than conventional assays.
The company's primary offerings were High Content Imaging and In Vitro Drug Screening services, which enabled high-throughput cellular analysis, compound evaluation, and pharmacological profiling. These services were positioned to help pharmaceutical and biotech companies evaluate drug candidates before committing to more expensive in vivo testing, addressing a key pain point in preclinical drug discovery workflows. OcellO operated with a horizontal segmentation approach, targeting drug discovery and development companies requiring reliable screening, efficacy testing, and high content imaging analysis.
OcellO was acquired by Crown Bioscience and fully integrated into the larger preclinical services organization's portfolio. The company no longer operates as an independent entity; its in vitro imaging and high content imaging capabilities have been incorporated as named service lines within Crown Bioscience's broader preclinical and drug discovery platform, which spans in vitro and in vivo models, biomarker services, and bioinformatics. Pricing was not publicly disclosed, as the offerings are now sold as part of Crown Bioscience's integrated service portfolio to enterprise pharmaceutical and biotech clients globally.
OcellO firmographics
Firmographics- Name
- OcellO
- Legal name
- OcellO
- Website
- https://ocello.nl
- Company type
- Private
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- OcellO was a Leiden-based biotech providing high content imaging and in vitro drug screening services to pharmaceutical and biotech companies. Founded in 2011, it was acquired by and fully integrated into Crown Bioscience's preclinical services portfolio.
- Ownership category
- akta.pro rank
OcellO industry classification
Industry- Product category
- Preclinical Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cellomics & High-Content Screening (HCS) Services (HLAGANAD)
- akta.pro secondary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where OcellO is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
OcellO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Distribution channels1 record
Marketing channels1 record
OcellO product offering
Product offeringCore offering
OcellO provides in vitro imaging and high-content screening services for drug discovery, including high content imaging for cellular analysis, comprehensive in vitro drug screening, cancer cell line panels for drug efficacy testing, and patient-derived organoid models for predictive drug screening. The company has been fully acquired and integrated into Crown Bioscience, with its capabilities now offered as part of Crown Bioscience's preclinical services portfolio.
Product overview
OcellO was a provider of in vitro imaging and high-content screening services for drug discovery. The company has been fully acquired and integrated into Crown Bioscience, functioning now as part of Crown Bioscience's expanded preclinical service offerings. OcellO's primary technology, High Content Imaging, has been incorporated into Crown Bioscience's integrated drug discovery platform alongside their other service lines including oncology solutions, preclinical services, biomarker services, and bioinformatics.
Differentiator
Problem solved
Functional benefit
Products and services
- High Content Imaging In vitro imaging technology and services that enable high-throughput cellular analysis for drug discovery applications. This was OcellO's primary offering, now fully integrated into Crown Bioscience's preclinical services portfolio and available to pharmaceutical and biotech clients globally.
- In Vitro Drug Screening Comprehensive in vitro screening services including cell-based assays and pharmacological profiling for compound evaluation. Provides drug discovery and development companies with preclinical testing capabilities using cell line panels and organoid models.
Companies that use OcellO
Customer profileSegments1 record
Ideal customer profiles1 record
OcellO technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OcellO partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
OcellO competitors and assessment
Company assessmentBroad incumbents
- Crown Bioscience: Strategic acquirer of OcellO and now the parent operating unit; offers the same high-content imaging and patient-derived organoid services as part of a global preclinical CRO portfolio spanning in vivo, biomarker and bioanalysis services.
- WuXi AppTec: Major CRO/CDMO with integrated in vitro biology, screening and oncology services that compete with Crown's/OcellO's preclinical discovery offerings, particularly for global pharma.
- Eurofins Discovery: Offers in vitro pharmacology, cell-based assays and screening panels, competing for the same drug-discovery and preclinical testing budgets as OcellO-derived services at Crown.
- Thermo Fisher Scientific (Cellomics): Owns the Cellomics high-content screening platform and offers assay services and instruments that compete with the OcellO HCI service within pharma preclinical workflows.
- Charles River Laboratories: Large preclinical CRO offering in vitro safety, cell-based assays and oncology discovery services that overlap with OcellO's high-content imaging and PDO screening capabilities for biopharma clients.
- PerkinElmer (Revvity): Sells Operetta and Phenix high-content imaging systems and provides cell-based assay services that overlap with OcellO's HCI-based screening offering for pharma R&D.
Direct peers
- Molecular Devices (Danaher): Provides high-content screening instruments, software and ImageXpress services used for phenotypic and cellular imaging screens, directly overlapping with OcellO's HCI service technology stack.
- Evotec: Global CRO with a deep in vitro and 3D biology / organoid service offering for drug discovery, directly competing with OcellO-derived HCS and organoid screening for pharma and biotech sponsors.
Emerging players
- Innoprot: Specialty provider of cell-based assays, 3D models and organoid services for preclinical drug discovery, an emerging player competing in the same HCS/organoid niche as OcellO.
- Phenomex (formerly Berkeley Lights): Provides single-cell and high-content functional screening platforms for therapeutic discovery, an emerging alternative to traditional high-content imaging CRO services.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
OcellO social profiles
Digital presenceOcellO financial estimates
Financial estimateRevenue estimate
Valuation estimate
OcellO leadership team
Management profileNumber of profiles
OcellO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OcellO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OcellO
What does OcellO do?
OcellO provides in vitro imaging and high-content screening services for drug discovery, including high content imaging for cellular analysis, comprehensive in vitro drug screening, cancer cell line panels for drug efficacy testing, and patient-derived organoid models for predictive drug screening. The company has been fully acquired and integrated into Crown Bioscience, with its capabilities now offered as part of Crown Bioscience's preclinical services portfolio.
Is OcellO a public or private company?
OcellO is a private company. It is classified as corporate owned and is currently acquired.
When was OcellO founded?
OcellO was founded in 2011. It employs 1 to 10 people.
Where is OcellO based?
OcellO is headquartered in Leiden, Netherlands, in the Europe region.
Who are OcellO's main competitors?
Broad incumbents on record are Crown Bioscience, WuXi AppTec, Eurofins Discovery, Thermo Fisher Scientific (Cellomics), Charles River Laboratories and PerkinElmer (Revvity). Direct peers are Molecular Devices (Danaher) and Evotec. Emerging players are Innoprot and Phenomex (formerly Berkeley Lights).
Does OcellO have an API?
No public API is recorded for OcellO.
What industry is OcellO in?
OcellO's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAGANAD, Cellomics & High-Content Screening (HCS) Services, with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.